渗出性年龄相关性黄斑变性抗血管内皮生长因子注射后黄斑下出血发生率
该回顾性临床队列研究分析了2015年1月至2023年11月全国聚合电子健康数据库中140915只新生血管性年龄相关性黄斑变性患眼,其中9107只眼伴黄斑下出血。结果显示,末次注射贝伐珠单抗的黄斑下出血发生率显著高于其他抗血管内皮生长因子药物(P ≤ .001),而法瑞西单抗或雷珠单抗末次注射的发生率显著较低(P = .0004)。作者认为法瑞西单抗可能较其他抗血管内皮生长因子注射对黄斑下出血更具保护作用。
要点
- 伴黄斑下出血眼中末次注射贝伐珠单抗者占37.8%,阿柏西普占35.4%,雷珠单抗占24.7%。
- 贝伐珠单抗末次注射的黄斑下出血发生率显著高于其他药物(P ≤ .001)。
- 法瑞西单抗或雷珠单抗末次注射的黄斑下出血发生率显著较低(P = .0004)。
核心结论
- 作者认为,在新生血管性年龄相关性黄斑变性患者中,法瑞西单抗可能较其他抗血管内皮生长因子注射对黄斑下出血更具保护作用。
研究设计与样本
- 回顾性临床队列研究,数据来自2015年1月至2023年11月的全国聚合电子健康数据库,共纳入140915只眼,其中9107只眼伴黄斑下出血。
- 采用比例卡方检验分析黄斑下出血患病率与抗血管内皮生长因子注射类型的关联,视力数据采用两独立样本t检验。
主要发现
- 伴黄斑下出血眼中,末次注射类型为贝伐珠单抗者3430只眼(37.8%),布罗鲁珠单抗-dbll者46只眼(0.51%),阿柏西普者3221只眼(35.4%),雷珠单抗者2246只眼(24.7%),法瑞西单抗-svoa者155只眼(1.7%)。
- 贝伐珠单抗末次注射的黄斑下出血发生率显著高于其他每种注射类型(P ≤ .001)。
- 法瑞西单抗-svoa或雷珠单抗末次注射的黄斑下出血发生率显著较低(P = .0004)。
- 法瑞西单抗-svoa和雷珠单抗组黄斑下出血诊断至末次注射的平均时间分别为48.9(标准差27.9)天(P < .02)和59.6(标准差38.2)天(P = .003),均显著短于其他注射组。
- 所有患者中,黄斑下出血前及出血后12个月的平均视力在各注射类型间无显著差异;行玻璃体切割术的患者中,黄斑下出血前及出血后12个月的平均视力在各注射类型间亦无显著差异。
关键数值与推荐
- 黄斑下出血发生率:贝伐珠单抗末次注射显著高于其他注射类型(P ≤ .001);法瑞西单抗-svoa或雷珠单抗末次注射显著较低(P = .0004)。
- 黄斑下出血诊断至末次注射平均时间:法瑞西单抗-svoa组48.9(标准差27.9)天(P < .02),雷珠单抗组59.6(标准差38.2)天(P = .003),均显著短于其他注射组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine rates of submacular hemorrhage in patients undergoing anti-vascular endothelial growth factor (VEGF) injections, comparing rates between specific anti-VEGF agents. DESIGN: Retrospective clinical cohort study. METHODS: All patients in the database from January 2015 to November 2023 with a diagnosis of neovascular age-related macular degeneration and accompanying submacular hemorrhage (SMH). SMH prevalence and associated anti-VEGF injection type were analyzed in 140,915 eyes (of which 9107 had SMH) in a nationwide aggregated electronic health care database using chi-square test of proportion. Visual acuity (VA) data was assessed using 2-sample independent t-tests. The primary outcome was rate of SMH per injection type. Secondary datapoints examined were time between SMH diagnosis and last anti-VEGF injection, number of injections before SMH, treatment interval at time of SMH, VA before and at 12 months after SMH, eyes undergoing pars plana vitrectomy (PPV) within 30 days of SMH, and VA before PPV and at 12 months after PPV. RESULTS: The last injection type in eyes with SMH was bevacizumab in 3430 (37.8%) eyes, brolucizumab-dbll in 46 (0.51%) eyes, aflibercept in 3221 (35.4%) eyes. Ranibizumab in 2246 (24.7%) eyes, and faricimab-svoa in 155 (1.7%) eyes. Rates of SMH were significantly higher (P ≤ .001) for last injection with bevacizumab compared to every other injection type. Rates of SMH were significantly lower (P = .0004) for last injection with faricimab-svoa or ranibizumab injections each had significantly shorter (mean and standard deviation 48.9 (27.9), P < .02; mean and standard deviation 59.6 (38.2), P = .003, respectively) mean time between SMH diagnosis and last injection than did patients undergoing any other injection. Mean VA before SMH and at 12 months after SMH did not significantly differ by injection type among all patients. The number of patients who underwent PPV were 52 (1.51%) for bevacizumab, 4 (8.7%) for brolucizumab-dbll, 58 (1.8%) for aflibercept, 41 (1.8%) for ranibizumab, and 3 (1.9%) for faricimab-svoa. Mean VA before SMH and at 12 months after SMH did not significantly differ by injection type in patients undergoing PPV. CONCLUSIONS: Faricimab may be more protective than other anti-VEGF injections against SMH in patients with neovascular age-related macular degeneration.
引用
- Kaufmann GT, Boucher N, Sharma C, et al. Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration. Am J Ophthalmol. 2024. PMID: 39455036. doi:10.1016/j.ajo.2024.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。